Ibex Medical Analytics has launched its Galen 3.0 cancer diagnostics platform, which has new detection capabilities and a broad feature set.
Galen is a clinical-grade, multi-tissue platform that has been developed to help pathologists detect and grade gastric, prostate and breast cancers.
It is claimed to be the first and most widely deployed, artificial intelligence (AI)-powered platform in pathology.
The platform helps to improve productivity, cancer detection quality, and user experience for pathologists.
It is used in usual clinical practice at hospitals, health systems and laboratories across the world.
Galen’s latest version, Galen 3.0, includes advanced versions of the company’s AI algorithms to detect cancer as well as other clinically relevant features in prostate, gastric and breast biopsies.
It includes expanded detection, user-interface and workflow integration capabilities.
The company trained the system’s Deep Learning networks on large data sets for high accuracy. The data sets included rare prostatic malignancies and were from labs that were digitized by multiple scanning systems.
The CE-marked platform calculates a Gleason score, the size of the tumor and a cancer slide percentage for each slide, which aims to help pathologists reduce subjectivity and review time.
It also includes an open Application Programming Interface (API) to expedite interoperability and can be easily integrated with digital pathology workflow solutions, lab information systems and image solutions.
Furthermore, Galen 3.0 includes new customizable reporting modules and enables customized slide and case reports according to patient requirements.
Ibex Product Management vice-president Issar Yazbin said: “With an estimated 1.9 million new cancer cases diagnosed in the United States alone this year, we are excited to bring Galen 3.0 to pathology labs worldwide, providing clinically validated, automated decision-support tools that help pathologists diagnose cancer more rapidly and more accurately to support the high demand.
“Keeping our customers’ needs central to our research and development, we are proud to deploy Galen 3.0, bringing enhanced detection capabilities, improved user experience, increased interoperability tools and ease of implementation into existing clinical workflows.”
In a separate development, the company has signed an agreement with Medipath to expand the deployment of AI solutions to additional labs in the Medipath network.